Amongst the highlights of Lp(a) research on show at the European Society of Cardiology congress in Munich, Germany (28-31 August 2026), were new insights into reductions in oxidised phospholipids associated with decreases in Lp(a) levels following novel siRNA therapy, evidence of the need for systematic Lp(a) testing for patients after percutaneous coronary intervention, and growing […]
Lepodisiran produces dose dependent reductions in oxidised phospholipids (OxPL) associated with Lp(a), with reductions most consistent at the 400 mg dose, and correlating closely with those seen in Lp(a) levels. These post hoc findings from the Phase 2 ALPACA trial in participants with elevated Lp(a) levels were presented by Professor Steven Nissen, Cleveland Clinic, Ohio, USA, at a Late Breaking Science Session at ESC 2026 congress, and published simultaneously in the Journal of the American College of Cardiology.
Systematic Lp(a) testing after percutaneous coronary intervention (PCI) may improve risk stratification, identify candidates for emerging therapies, and guide implementation of targeted secondary prevention strategies in routine cardiovascular (CV) practice. This was the conclusion of Dr Eva Steinacher, Medical University of Vienna, Austria, and colleagues, following an analysis of data from 5,942 consecutive patients undergoing PCI, to investigate their eligibility for emerging therapies and apheresis.
Adding to the debate about the potential need for repeat Lp(a) testing comes an analysis of Lp(a) measurements from participants in the placebo arm of the ODYSSEY OUTCOMES study of PCSK9i therapy with alirocumab in high risk patients on optimised statin therapy following an acute coronary syndrome (ACS) event.
Elevated Lp(a) independently identifies a high-risk calcific coronary phenotype beyond LDL-C levels, an intravascular ultrasound (IVUS) study carried out by Dr Yu Iemeura and colleagues at Saitama Medical Center, Kawagoe, Japan, has shown.
The novel oral small molecule inhibitor of Lp(a) particle assembly, HRS-5346, reduces Lp(a) levels in patients at high cardiovascular risk and with Lp(a) ≥150 nmol/L and is generally well tolerated, according to Phase 2 data presented by Dr Dan Zhu, from Peking University Third Hospital, Beijing, China.
